Based on the industrial foundation and future development direction, Foshan had proposed to build a new development system for “2+2+4” advanced manufacturing clusters. As the key to capture the development opportunity of Guangdong-Hong Kong-Macao Greater Bay Area, Sanlongwan Innovation Cluster (hereinafter referred as Sanlongwan) has set up six biomedical industry platforms to develop biomedical industry in Foshan.
Sanlongwan: to propose solutions concerning difficulties of conversion
When Lu Yi, Secretary of the CPC Foshan Municipal Committee, conducted research investigation in Sanlongwan on July 11th, he pointed out that Sanlongwan should accelerate the construction of high-level innovative carriers such as Jihua Lab. It is reported that, Jihua Lab had planned its research direction in six subjects including biomedical engineering, and high-quality instruments and equipment for life science. It is planned to operate officially in June, 2020.
The person in charge of the Sanlongwan Management Committee introduced that biomedical technology needs to pass animal test, clinical phase I, II and III trials so as to successfully obtain marketing approval. During the process, the technology must also gain approval from medical institutions and third-party medical service providers before having access to patients and consumers.
So far, Sanlongwan and the Institute of Microbiology of Chinese Academy of Sciences established a “Health Toxicology Evaluation Center” to conduct preclinical evaluations on the safety and therapeutic effects of new drugs, medical devices, and new chemical substances. At the same time, Sanlongwan introduced the first Sino-German contract research organization (CRO) and contract manufacture organization (CMO) of biomacromolecule drugs in South China, which greatly accelerated the speed of innovation and generic drug marketing.
Towns: to build achievement transformation bases of biomedical science and technology
In order to bring in international resources and carry the innovative transformation function of Sanlongwan, Lecong Town has built two incubator platforms including International Innovation and Transformation Incubation Center of Bio-industry, and Evian International R&D Hall; it has undertaken six industrial research and development platforms, including 30,000 square meters of industrial acceleration platform for biomedical R&D and pilot institutions. Meanwhile, it has introduced more than 30 biomedical innovation research teams such as the Academician Chen Runsheng of the Chinese Academy of Sciences.
Lecong will accelerate the construction of biomedical industry innovation platform such as Kehui Life Science and Technology Industry Center and Guangdong Medical Data Integration Application Engineering Technology Research Center. At the same time, it will improve the construction and service of incubator parks such as the International Innovation and Transformation Bio-industry Incubation Center and the Foshan-Chinese Academy of Sciences Life and Health Center.
Enterprises: to lead biomedical science and technology achievements transformation
Sanlongwan devotes to build an industry development system of “Incubator + Accelerator + Industrial Park” which encourages scientists to lead the role of model companies and projects.
Bi Lijun, from Institute of Biophysics, Chinese Academy of Sciences, established TBhealthcare at the end of 2012. He developed the first high-precision products such as the Mycobacterium tuberculosis proteome chip and bacterial ultrasonic dispersion counter in the world.
Moreover, in Sanshan, Nanhai, Casangels has developed into a company in the filed of oral prosthetics, breaking through the technology monopoly of Europe and America, and becoming the industry leader in the world’s first 3D printing personalized oral cranial surface repair.
Except TBHealthcare and Casangels, Sanlongwan introduces more than 40 biopharmaceutical companies to promote the transformation of biomedical science and technology and push the development of biomedical industry.